Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: A nationwide cohort study
Journal
Pharmacotherapy
Journal Volume
42
Journal Issue
6
Pages
483
Date Issued
2022
Author(s)
Abstract
Clinical trials have suggested that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may be associated with a higher risk of biliary-related diseases in patients with type 2 diabetes. Limited real-world studies have examined the comparative biliary safety of GLP-1RAs versus other antihyperglycemic drugs. We aimed to estimate the comparative risk of biliary-related diseases between GLP-1RAs and sodium glucose cotransporter 2 inhibitors (SGLT2is), which are indicated for patients with similar diabetes severity in Taiwan.
Subjects
acute cholangitis; acute cholecystitis; biliary-related diseases; cholecystectomy; choledocholithiasis; cohort study; glucagon-like peptide-1 receptor agonists; pharmacoepidemiology; sodium glucose cotransporter 2 inhibitors; type 2 diabetes
SDGs
Publisher
WILEY
Type
journal article